Tags

Type your tag names separated by a space and hit enter

Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice.
Virol J. 2012 Dec 29; 9:322.VJ

Abstract

BACKGROUND

Immunity to conserved viral antigens is an attractive approach to develop a universal vaccine against epidemic and pandemic influenza. A nucleoprotein (NP)-based vaccine has been explored and preliminary studies have shown promise. However, no study has explored the immunity and cross-protective efficacy of recombinant NP derived from Escherichia coli compared with recombinant vaccinia virus (Tiantan).

METHODS

Recombinant NP protein (rNP) from influenza virus A/Jingke/30/95(H3N2) was obtained from E. coli and recombinant vaccinia virus (Tiantan) RVJ1175NP. Purified rNP without adjuvant and RVJ1175NP were used to immunize BALB/c mice intramuscularly. Humoral immune responses were detected by ELISA, while cell-mediated immune responses were measured by ex vivo IFN-γ ELISPOT and in vivo cytotoxicity assays. The cross-protective efficacy was assessed by a challenge with a heterosubtype of influenza virus A/PR/8/34(H1N1).

RESULTS

Our results demonstrate that a high dose (90 μg) of rNP induced NP-specific antibodies and T cell responses that were comparable with those of RVJ1175NP in mice. Importantly, the survival ratio (36, 73, and 78%) of the vaccinated mice after the influenza virus A/PR/8/34(H1N1) challenge was rNP vaccine dose-dependent (10, 30, and 90 μg, respectively), and no significant differences were observed between the rNP- and RVJ1175NP-immunized (91%) mice.

CONCLUSIONS

Influenza A virus NP derived from E. coli or recombinant vaccinia (Tiantan) virus elicited cross-protection against influenza virus in mice, and the immune response and protective efficacy of rNP were comparable to RVJ1175NP. These data provide a basis for the use of prokaryotically expressed NP as a candidate universal influenza vaccine.

Authors+Show Affiliations

Biotech Center for Viral Disease Emergency, National Institute for Viral Disease Control and Prevention (IVDC), Chinese Center for Disease Control and Prevention (CCDC), Changbai Road 155, Changping District, Beijing, 102206, People's Republic of China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23272943

Citation

Huang, Baoying, et al. "Influenza a Virus Nucleoprotein Derived From Escherichia Coli or Recombinant Vaccinia (Tiantan) Virus Elicits Robust Cross-protection in Mice." Virology Journal, vol. 9, 2012, p. 322.
Huang B, Wang W, Li R, et al. Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice. Virol J. 2012;9:322.
Huang, B., Wang, W., Li, R., Wang, X., Jiang, T., Qi, X., Gao, Y., Tan, W., & Ruan, L. (2012). Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice. Virology Journal, 9, 322. https://doi.org/10.1186/1743-422X-9-322
Huang B, et al. Influenza a Virus Nucleoprotein Derived From Escherichia Coli or Recombinant Vaccinia (Tiantan) Virus Elicits Robust Cross-protection in Mice. Virol J. 2012 Dec 29;9:322. PubMed PMID: 23272943.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice. AU - Huang,Baoying, AU - Wang,Wenling, AU - Li,Renqing, AU - Wang,Xiuping, AU - Jiang,Tao, AU - Qi,Xiangrong, AU - Gao,Yingying, AU - Tan,Wenjie, AU - Ruan,Li, Y1 - 2012/12/29/ PY - 2012/07/16/received PY - 2012/12/12/accepted PY - 2013/1/1/entrez PY - 2013/1/1/pubmed PY - 2013/7/11/medline SP - 322 EP - 322 JF - Virology journal JO - Virol J VL - 9 N2 - BACKGROUND: Immunity to conserved viral antigens is an attractive approach to develop a universal vaccine against epidemic and pandemic influenza. A nucleoprotein (NP)-based vaccine has been explored and preliminary studies have shown promise. However, no study has explored the immunity and cross-protective efficacy of recombinant NP derived from Escherichia coli compared with recombinant vaccinia virus (Tiantan). METHODS: Recombinant NP protein (rNP) from influenza virus A/Jingke/30/95(H3N2) was obtained from E. coli and recombinant vaccinia virus (Tiantan) RVJ1175NP. Purified rNP without adjuvant and RVJ1175NP were used to immunize BALB/c mice intramuscularly. Humoral immune responses were detected by ELISA, while cell-mediated immune responses were measured by ex vivo IFN-γ ELISPOT and in vivo cytotoxicity assays. The cross-protective efficacy was assessed by a challenge with a heterosubtype of influenza virus A/PR/8/34(H1N1). RESULTS: Our results demonstrate that a high dose (90 μg) of rNP induced NP-specific antibodies and T cell responses that were comparable with those of RVJ1175NP in mice. Importantly, the survival ratio (36, 73, and 78%) of the vaccinated mice after the influenza virus A/PR/8/34(H1N1) challenge was rNP vaccine dose-dependent (10, 30, and 90 μg, respectively), and no significant differences were observed between the rNP- and RVJ1175NP-immunized (91%) mice. CONCLUSIONS: Influenza A virus NP derived from E. coli or recombinant vaccinia (Tiantan) virus elicited cross-protection against influenza virus in mice, and the immune response and protective efficacy of rNP were comparable to RVJ1175NP. These data provide a basis for the use of prokaryotically expressed NP as a candidate universal influenza vaccine. SN - 1743-422X UR - https://www.unboundmedicine.com/medline/citation/23272943/Influenza_A_virus_nucleoprotein_derived_from_Escherichia_coli_or_recombinant_vaccinia__Tiantan__virus_elicits_robust_cross_protection_in_mice_ L2 - https://virologyj.biomedcentral.com/articles/10.1186/1743-422X-9-322 DB - PRIME DP - Unbound Medicine ER -